Institut Paoli Calmettes Myelodysplastic Syndromes Database

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03275480

Enrollment

10000

Registered

2017-09-07

Start date

2016-01-18

Completion date

2030-12-31

Last updated

2019-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndromes

Brief summary

Database of Institut Paoli-Calmettes patients diagnosed with Myelodysplastic Syndromes

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with a diagnosis of Myelodysplastic Syndromes

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Survival of patients with myelodysplastic syndrome(MDS)	10 years	Overall survival of all patients with MDS who are taken in charge in Institut Paoli Calmettes Cancer Center

Secondary

Measure	Time frame	Description
Collection of patients characteristics	10 years	Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies

Countries

France

Contacts

Primary ContactDominique Genre, MD

drci.up@ipc.unicancer.fr+33491223778

Backup ContactLilian Laborde

abordel@ipc.unicancer.fr+33491223778

Outcome results